If I was at Wed’s Q2 meeting here’s a Q I would ask regarding Belinostat re: solid tumors
As previously expressed on this board, I am frustrated with SPPI’s slow crawl with regards to initiating Belinostat pivotal studies and would love to get some hindsight on it. So here's my Q.
- The CUP study was not set up or powered to detect significant statistical differences due to the low # of patients (89) being tested and to the many subpopulations where the cancer could originate from yet we saw clinical activity i.e. I believe it was a 30% survival improvement trending toward statistical significance. I would think future investigation is definitely warranted but have not heard anything in those regards. Was wondering why nothing has been started up to now? Do you think the results weren’t good enough to warrant further studies?
Yeah, you're right. They definitely don't have the resources at this time. Earlier in the year, there was that rumor (article in PharmaTimes) that Astra Zeneca was interested in Topotarget; too bad nothing happened. Large Pharma would have got things moving.